Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Targeted therapy for hepatocellular carcinoma
The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of develo** hepatocellular carcinoma (HCC). Even after complete HCC …
are at a high risk of develo** hepatocellular carcinoma (HCC). Even after complete HCC …
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline
JD Gordan, EB Kennedy, GK Abou-Alfa… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …
Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update
JD Gordan, EB Kennedy, GK Abou-Alfa… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE To update an evidence-based guideline to assist in clinical decision-making for
patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO convened an …
patients with advanced hepatocellular carcinoma (HCC). METHODS ASCO convened an …
Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy
Simple Summary Hepatocellular carcinoma (HCC) constitutes a major health burden,
accounting for> 80% of primary liver cancers globally. Inflammation has come into the …
accounting for> 80% of primary liver cancers globally. Inflammation has come into the …
[HTML][HTML] Epigenetic associations between lncRNA/circRNA and miRNA in hepatocellular carcinoma
Simple Summary Non-coding RNAs such as microRNAs, long non-coding RNAs, and
circular RNAs contribute to the development and progression of hepatocellular carcinoma …
circular RNAs contribute to the development and progression of hepatocellular carcinoma …
Identification of a ferroptosis-related signature model including mRNAs and lncRNAs for predicting prognosis and immune activity in hepatocellular carcinoma
ZA Chen, H Tian, DM Yao, Y Zhang, ZJ Feng… - Frontiers in …, 2021 - frontiersin.org
Background Ferroptosis is a novel form of regulated cell death involved in tumor
progression. The role of ferroptosis-related lncRNAs in hepatocellular carcinoma (HCC) …
progression. The role of ferroptosis-related lncRNAs in hepatocellular carcinoma (HCC) …
New therapeutic interventions for advanced hepatocellular carcinoma
Background Advanced hepatocellular carcinoma (HCC) portends a poor prognosis;
however recent advances in first‐line and second‐line treatment options should yield …
however recent advances in first‐line and second‐line treatment options should yield …
Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma
X Zhang, J Wang, J Shi, X Jia, S Dang… - JAMA Network …, 2021 - jamanetwork.com
Importance Atezolizumab plus bevacizumab as a first-line therapy for patients with
unresectable or metastatic hepatocellular carcinoma has been shown to improve overall …
unresectable or metastatic hepatocellular carcinoma has been shown to improve overall …
Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: a …
Abstract Background & Aims In patients with unresectable hepatocellular carcinoma (HCC),
the combination of atezolizumab and bevacizumab improved progression‐free survival …
the combination of atezolizumab and bevacizumab improved progression‐free survival …